2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1963 IL1RAP-targeting bispecific engager as a novel therapeutic strategy for myeloproliferative neoplasms

Yile Zhou, MD, PhD, Miso Park, PhD2, Dandan Zhao, PhD3, Xin Yang4, Lucy Ghoda, PhD5, Guido Marcucci, MD6, John Williams, PhD7, Bin Zhang, PhD8, Idoroenyi Amanam, MD9
1 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Department of Cancer Biology and Molecular Medicine, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
3 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
4 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
5 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
6 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, United States
7 Department of Cancer Biology and Molecular Medicine, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
8 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States
9 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, United States

Background: Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are driven predominantly by JAK2, CALR, or MPL mutations, yet disease progression reflects interplay between these cell-intrinsic drivers and extrinsic inflammatory signaling. JAK inhibitors improve symptoms and reduce splenomegaly but do not eradicate the malignant clone. Interleukin-1 receptor accessory protein (IL1RAP) is a cell surface coreceptor required for IL-1R1 signaling and participates in FLT3 and c-KIT signaling, linking inflammatory and growth-factor pathways implicated in malignant stem/progenitor cell persistence. We previously established IL1RAP as a target for immune-mediated therapy in AML (J Hematol Oncol 2024 & 2025). Prior studies linked IL1RAP expression to overtly fibrotic and JAK2V617F-positive MPN and showed compartment-specific expression across CD34?CD38? stem and CD34?CD38? progenitor cells (PLoS One. 2019; Nat Commun. 2022; Am J Hematol. 2023), but did not address therapeutic targetability. We therefore evaluated IL1RAP expression and therapeutic targeting using an IL1RAP×CD3 T-cell engager (TCE) in MPN models.

Methods: IL1RAP surface expression was assessed by flow cytometry in the MPN-derived cell lines HEL92.1.7, SET-2, ELF-153, HNT-34, and MARIMO, as well as in bulk, CD34?CD38?, and CD34?CD38? and CD41+ populations from primary MPN patient samples. To targeting IL1RAP positive MPN, we developed a novel IL1RAP×CD3 bispecific TCE, αIL1RAP–αCD3, engineered through covalent stabilization of Fc-Fc interactions to enable bivalent target binding and monovalent T-cell engagement (Nat Commun. 2026). Its antitumor activity was evaluated in vitro and in MPN xenograft models in vivo.

Results: Analysis of published transcriptomic datasets (GSE53482, GSE159514) demonstrated significantly higher IL1RAP expression in MPN samples than in healthy donors, particularly in primary myelofibrosis (PMF). Within the myelofibrosis subtypes, IL1RAP expression increased from pre-fibrotic PMF (pre-PMF) to overt PMF and was the highest in post–polycythemia vera myelofibrosis (post-PV MF), suggesting an association with fibrotic progression. Among molecular subgroups, IL1RAP expression was significantly higher in JAK2V617F-mutant than in CALR-mutant or triple-negative MPNs. Consistent with these transcriptomic data, flow cytometric analysis of MPN cell lines and primary patient samples in our center demonstrated increased surface expression of IL1RAP, with a higher median fluorescence intensity in MPN patient samples than in healthy donor samples (622.5 vs. 283.5), further supporting IL1RAP as a potential therapeutic target in MPNs.

Flow cytometric analysis demonstrated that αIL1RAP–αCD3 specifically bound to human T cells as well as the IL1RAP-expressing MPN cell lines HEL92.1.7 (JAK2V617F) and MARIMO (CALR type I). In the absence of IL1RAP-expressing target cells, αIL1RAP–αCD3 did not induce T-cell activation, as assessed by lack of CD25 and CD69 expression. In coculture with healthy donor T cells, αIL1RAP–αCD3 induced target-dependent T-cell activation and potent, dose-dependent cytotoxicity against both HEL92.1.7 and MARIMO cells. At an E:T ratio of 5:1, the 48-hour concentrations producing 50% inhibition of target cell viability were 0.107nM (HEL92.1.7) and 0.062nM (MARIMO). In luciferase-expressing HEL92.1.7 and MARIMO cell-derived xenograft (CDX) models, αIL1RAP–αCD3 plus human T cells significantly reduced disease burden (HEL92.1.7: 8.5×108 vs. 2.9×108 photons/sec at day 22; MARIMO: 1.9×109 vs. 7.5×108 photons/sec at day 22) and prolonged survival  (HEL92.1.7: 72.5 vs. 55 days, P = 0.021; MARIMO: 37 vs. 32 days, P = 0.0018) when compared with untreated or control IgG-treated mice. αIL1RAP–αCD3 also induced target-dependent T-cell activation and potent, dose-dependent cytotoxicity against MPN patient cells, with 48-hour IC50 values of 0.047nM at E:T ratio of 5:1. Evaluation of αIL1RAP–αCD3 in MPN patient-derived xenograft models is ongoing.

Conclusions: IL1RAP is a therapeutically actionable surface target in the MPN models evaluated. αIL1RAP–αCD3 redirected T cells against IL1RAP-expressing JAK2V617F- and CALR-mutant MPN, producing target-dependent cytotoxicity in vitro and prolonging survival in vivo. These findings establish proof-of-concept for an IL1RAP-directed TCE in MPN, and validation in additional models is ongoing.

Yile Zhou, MD, PhD: No relevant conflicts of interest to declare.